Epineuron Secures FDA 510(k) Clearance for Evala® Nerve Stimulator

Epineuron, a Mississauga, Ontario-based medical device company, has announced the FDA 510(k) clearance for its Evala® Nerve Stimulator, a handheld device designed for intraoperative electrical stimulation. This innovative technology aims to assist surgeons in accurately identifying and evaluating nerves of varying sizes during surgical procedures. The announcement marks a significant enhancement to Epineuron’s portfolio and expands its bioelectronic solutions for peripheral nerve care.

Dr. Jana Dengler, a peripheral nerve surgeon at Sunnybrook Health Sciences Centre in Toronto, was among the first to utilize the Evala® device. She expressed her satisfaction with the instrument's versatility, particularly in challenging scenarios such as scarred revision surgeries and nerve transfers, highlighting its effectiveness even under conditions like extended tourniquet time.

Sergio Aguirre, the CEO of Epineuron, emphasized the company's commitment to addressing the needs of surgeons who require more than conventional nerve stimulation devices. He noted that the Evala® technology complements their existing product, PeriPulse®, creating an integrated ecosystem for nerve care. This combined approach aims to enhance surgical efficiency while simultaneously protecting nerves during procedures and boosting their regeneration afterward. By streamlining the surgical workflow, Epineuron is focused on improving patient recovery outcomes.

The introduction of Evala® reflects Epineuron’s dedication to advancing bioelectronic medicine in the realm of peripheral nerve care, illustrating the company's ongoing commitment to both clinicians and their patients. Epineuron aims to empower healthcare professionals with simple, effective solutions that facilitate decision-making and bring the therapeutic potential of the peripheral nervous system to the forefront.

For further details, Epineuron invites interested parties to visit their website at www.epineurontech.com.

In summary, Epineuron Technologies Inc. stands at the intersection of innovation and patient care, committed to transforming the landscape of nerve evaluation and regeneration through its proprietary bioelectronic solutions. The FDA clearance of Evala® is a crucial step in their mission to improve the quality of life for patients while equipping clinicians with advanced tools for nerve management.